About Alger
Alger is a venture capital firm founded in 1964. It is primarily based out of New York City, United States. As of Dec 2025, Alger has invested in 7 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series F round of Impulse Dynamics Overall, Alger portfolio has seen 2 unicorns and 2 acquisitions including key companies like SandboxAQ, Forte Biosciences and Intarcia. A lot of funds co-invest with Alger, with names like Yann LeCun sharing a substantial percentage of its portfolio. Alger has team of 58 people including 2 partners.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Post IPO & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Alger's List of Top Investments
Alger has a portfolio of 7 companies, including 2 unicorns. Their most notable investments are in ChoiceStream and SandboxAQ.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 1 other sectors, across stages such as Series B, Post IPO and 4 more. Here is the list of top investments by Alger:
1. SandboxAQ
Developer of quantitative artificial intelligence models for various industry applications. The company provides large quantitative models rooted in science and engineered for impact. These models offer real-world solutions with clear outputs and reduced uncertainty. The company's models are deployed in areas such as drug discovery, new chemicals and materials, cybersecurity, navigation, and medical diagnostics.
Key facts about SandboxAQ
- Founded Year: 2022
- Location: Palo Alto (United States)
- Valuation: $*****
- Stage: Series E
- Total Funding till date: $950M
- Employee Count: 374 as on Aug 31, 2026
- Investors: T. Rowe Price, BNP Paribas and 34 Others
- Latest Funding Round: Series E, Apr 04, 2025, $*****
- Highlight: Editors' Pick
Impulse Dynamics is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed, Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer is CE is FDA approved.
Key facts about Impulse Dynamics
- Founded Year: 1998
- Location: Marlton (United States)
- Valuation: $*****
- Stage: Series F
- Total Funding till date: $685M
- Employee Count: 241 as on May 31, 2026
- Investors: Perceptive Advisors, Redmile Group and 16 Others
- Latest Funding Round: Series F, Dec 10, 2025, $*****
- Highlight: Editors' Pick
Forte Biosciences is a developer of therapeutic solutions for treating inflammatory skin diseases. The company has developed its lead topical product, FB-401 made of strains of a commensal gram-negative bacteria called as Roseomonas mucosa to treat inflammatory skin disease.
Key facts about Forte Biosciences
- Founded Year: 2017
- Location: Torrance (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 16 as on Mar 31, 2026
- Investors: BVF Partners, Janus Henderson Investors and 6 Others
- Latest Funding Round: Post IPO, Nov 20, 2024, $*****
- Highlight: Acquired

4. Intarcia
Intarcia Therapeutics offers a drug delivery platform technology. The product is a subcutaneous osmotic mini-pump containing the necessary volume of the drug. Once implanted under the skin, water from the extracellular fluid enters the device and osmotic pressure drives a piston which delivers the drug.
Key facts about Intarcia
- Founded Year: 1995
- Location: Boston (United States)
- Valuation: $*****
- Stage: Series J
- Total Funding till date: $1.89B
- Employee Count: 68 as on Aug 31, 2026
- Investors: Adams Street Partners, Brentwood Associates and 42 Others
- Latest Funding Round: Series J, Jan 14, 2020, $*****
- Highlight: Editors' Pick
Developer of antiviral and other therapeutics using proprietary drug discovery platform. The company's research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.
Key facts about Prosetta Biosciences
- Founded Year: 2003
- Location: San Francisco (United States)
- Annual Revenue: 0 - ₹10 Cr as on Mar 31, 2025
- Stage: Series D
- Total Funding till date: $35.1M
- Employee Count: 23 as on Aug 31, 2026
- Investors: Takeda, Alger and 2 Others
- Latest Funding Round: Series D, Nov 20, 2015, $*****
Alger's Year-on-Year Investment Trends
Alger has invested in 8 companies over the last 12 years, with an average of 0 new investment annually in the last 10 years. In 2025, it made 2 investments. Its most recent first time investment was in SandboxAQ and most recent follow-on round was in Impulse Dynamics.Alger's Investments by Stage
Alger has made 2 investments in Series B stage with an average round size of $10.9M, 1 investment in Post IPO stage with an average round size of $37.9M and 1 investment in Series A stage with an average round size of $300M.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Post IPO | 1 |
Series A | 1 |
Series D | 1 |
Series E | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Alger's Investments by Sector
Alger has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Artificial Intelligence - Industry Applications, Enterprise Infrastructure and High Tech. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 2 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
Enterprise Applications | 2 |
Artificial Intelligence - Industry Applications | 1 |
Enterprise Infrastructure | 1 |
High Tech | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Alger's Investments by Geography
Alger has made most investments in United States (7).Alger's recent investments
Alger has not made any investment in 2026 so far.Here are the most recent investments by Alger:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 10, 2025 | United States | Series F | 4532 | [+3] | |
Apr 04, 2025 | United States | Series E | 4502 | [+10] | |
Dec 18, 2024 | United States | Series A | 6557 | [+11] | |
Nov 20, 2024 | United States | Post IPO | 4963 | [+5] | |
Feb 05, 2024 | United States | Series E | 7088 | [+2] |
Unicorns in Alger's Portfolio
Alger has 2 unicorns in its portfolio - SandboxAQ and Intarcia. The most recent unicorn in their portfolio is SandboxAQ. It became a unicorn in 2024.Here is a list of unicorns in Alger's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
66 | Developer of quantitative artificial intelligence models for various industry applications | 2022 | Palo Alto | Series E | gxijccs | ||
47 | Provider of osmotic pump for subcutaneous drug delivery | 1995 | Boston | Series J | {ucbgps |
Acquired companies in Alger's Portfolio
2 companies from Alger's portfolio have been acquired. The most recent acquisition was Forte Biosciences in Jul 2026 by argenx for $*****.Here are Alger's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 27, 2026 | Nov 20, 2024 | Post IPO | 4012 | |
Dec 21, 2016 | Aug 15, 2014 | Series B | 9034 |
Team profile of Alger
Alger has a team of 58 members including 2 Partners and 34 Principals located in United States, United Kingdom and 1 more location. Alger's team does not sit on the board of any company as of now.Co-investors of Alger
Over the past 12 years, 77 investors have co-invested in Alger's portfolio companies. This includes funds and angels.
- Invested before Alger: Schmidt’s, Breyer Capital and 41 others have invested in rounds before Alger. There is 1 company where Schmidt’s has invested before Alger and 1 company where Breyer Capital has invested before Alger.
- Top Co-investors of Alger: 19 investors entered a company along with Alger. These include investors like Yann LeCun (1 company).
- Invested after Alger: A total of 15 investors have invested in Alger's portfolio after their investments. Top Investors include Alphabet (1 company), BNP Paribas (1 company) and Nvidia (1 company).
Recent News related to Alger
•
•
•
•
Alger SICAV - Alger American Asset Growth Fund Q2 2026 Portfolio UpdateSeeking Alpha•Aug 19, 2026•Alger
•
•
•
•
•
Take-Two Interactive Software, Inc. $TTWO Shares Acquired by Fred Alger Management LLCMarketBeat•Mar 17, 2026•Alger, Take-Two Interactive
•